PRESS RELEASE published on 12/29/2025 at 08:00, 4 months 11 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 12/29/2025 at 08:00, 4 months 11 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 4 months 18 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 4 months 18 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
BRIEF published on 12/22/2025 at 07:05, 4 months 18 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
BRIEF published on 12/22/2025 at 07:05, 4 months 18 days ago Délivrance d'une autorisation d'accès compassionnel pour GS010/LUMEVOQ® Thérapie Génique GenSight Biologics NOHL Accès Compassionnel ANSM
PRESS RELEASE published on 12/22/2025 at 07:00, 4 months 18 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
PRESS RELEASE published on 12/22/2025 at 07:00, 4 months 18 days ago Informations privilégiées / Autres communiqués GenSight Biologics obtient une autorisation d'accès compassionnel en France pour GS010/LUMEVOQ dans le traitement de la NOHL liée à la mutation ND4 Thérapie Génique GenSight Biologics NOHL GS010/LUMEVOQ Autorisation D'accès Compassionnel
BRIEF published on 11/13/2025 at 18:02, 5 months 26 days ago Franchissement de seuils par Heights Capital Management Obligations Convertibles Franchissement De Seuils GenSight Biologics Actions Et Droits De Vote Heights Capital
BRIEF published on 11/13/2025 at 18:02, 5 months 26 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
Published on 05/09/2026 at 01:30, 23 hours 40 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 1 hour ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/09/2026 at 19:05, 6 hours 4 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 4 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 5 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 6 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 5 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 5 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 6 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 6 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 6 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
